Unicycive Therapeutics, Inc. Common Stock
UNCY
UNCY: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
moreShow UNCY Financials
Recent trades of UNCY by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by UNCY's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use Aug. 09, 2022
Federal grants, loans, and purchases
Followers on UNCY's company Twitter account
Number of mentions of UNCY in WallStreetBets Daily Discussion
Recent insights relating to UNCY
Recent picks made for UNCY stock on CNBC
ETFs with the largest estimated holdings in UNCY
Flights by private jets registered to UNCY